T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PLG
976
Platinum Group Metals
PLG
$189M
| $34.2M | 0.01% |
286,684
+4,156
| +1% | +$450K |
|
|
IDIX
977
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $33.8M | 0.01% |
1,404,444
-6,817,349
| -83% | -$71.1M |
|
978
Team
TISI
$101M
| $33.8M | 0.01% |
82,416
-5,350
| -6% | -$2.22M |
|
|
TCF
979
DELISTED
TCF Financial Corporation
TCF
| $33.7M | 0.01% |
2,059,189
-23,021
| -1% | -$369K |
|
980
Outfront Media
OUT
$5.29B
| $33.6M | 0.01% |
+1,375,141
| New | +$32.4M |
|
981
Saga Communications
SGA
$64.6M
| $33.5M | 0.01% |
784,843
| – | – |
|
982
AptarGroup
ATR
$8.43B
| $33.5M | 0.01% |
499,360
-13,600
| -3% | -$904K |
|
983
American Vanguard Corp
AVD
$64M
| $33.4M | 0.01% |
2,526,682
+67,380
| +3% | +$1.1M |
|
984
STRATTEC Security
STRT
$341M
| $33.4M | 0.01% |
517,890
-100
| -0% | -$6.75K |
|
985
Public Service Enterprise Group
PEG
$37.8B
| $33.3M | 0.01% |
815,726
+25,200
| +3% | +$979K |
|
986
Azenta
AZTA
$1.47B
| $33M | 0.01% |
3,060,404
+10,300
| +0.3% | +$104K |
|
987
First Solar
FSLR
$24B
| $32.8M | 0.01% |
462,081
-42,700
| -8% | -$2.83M |
|
|
WIRE
988
DELISTED
Encore Wire Corp
WIRE
| $32.1M | 0.01% |
654,637
+4,342
| +0.7% | +$211K |
|
|
LDR
989
DELISTED
Landauer Inc
LDR
| $31.7M | 0.01% |
755,870
+350
| +0% | +$15.7K |
|
990
PennyMac Financial
PFSI
$4B
| $31.7M | 0.01% |
2,086,150
-1,585
| -0.1% | -$25.3K |
|
|
CNR
991
DELISTED
Cornerstone Building Brands, Inc.
CNR
| $31.7M | 0.01% |
1,629,791
+880,222
| +117% | +$15M |
|
|
MNTA
992
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $31.6M | 0.01% |
2,618,312
-660,927
| -20% | -$7.81M |
|
993
Expeditors International
EXPD
$24B
| $31.6M | 0.01% |
714,670
-865,197
| -55% | -$37.2M |
|
994
Welltower
WELL
$166B
| $31.3M | 0.01% |
499,530
+21,529
| +5% | +$1.35M |
|
995
Hawkins
HWKN
$2.67B
| $31.3M | 0.01% |
1,683,622
+61,740
| +4% | +$1.11M |
|
996
FRP Holdings
FRPH
$425M
| $31.2M | 0.01% |
1,785,216
+12,200
| +0.7% | +$209K |
|
997
Vale
VALE
$61.4B
| $31.2M | 0.01% |
2,357,963
-353,440
| -13% | -$4.77M |
|
998
Healthpeak Properties
DOC
$14.2B
| $31.2M | 0.01% |
826,860
+34,917
| +4% | +$1.31M |
|
|
MTSC
999
DELISTED
MTS Systems Corp
MTSC
| $30.9M | 0.01% |
455,350
+8,170
| +2% | +$545K |
|
|
ALEX
1000
DELISTED
Alexander & Baldwin
ALEX
| $30.8M | 0.01% |
743,190
+46,220
| +7% | +$1.82M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.